Endothelial function, blood pressure control, and risk modification: impact of irbesartan alone or in combination

Giuseppe Derosa
Sibilla AT Salvadeo

Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy

Abstract: Irbesartan, an angiotensin II type 1 receptor antagonist, is approved as monotherapy, or in combination with other drugs, for the treatment of hypertension in many countries worldwide. Data in the literature suggest that irbesartan is effective for reducing blood pressure over a 24-hour period with once-daily administration, and slows the progression of renal disease in patients with hypertension and type 2 diabetes. Furthermore, irbesartan shows a good safety and tolerability profile, compared with angiotensin II inhibitors and other angiotensin II type 1 receptor antagonists. Thus, irbesartan appears to be a useful treatment option for patients with hypertension, including those with type 2 diabetes and nephropathy. Irbesartan has an inhibitory effect on the pressor response to angiotensin II and improves arterial stiffness, vascular endothelial dysfunction, and inflammation in hypertensive patients. There has been considerable interest recently in the renoprotective effect of irbesartan, which appears to be independent of reductions in blood pressure. In particular, mounting data suggests that irbesartan improves endothelial function, oxidative stress, and inflammation in the kidneys. Recent studies have highlighted a possible role for irbesartan in improving coronary artery inflammation and vascular dysfunction. In this review we summarize and comment on the most important data available with regard to antihypertensive effect, endothelial function improvement, and cardiovascular risk reduction with irbesartan.

Keywords: blood pressure, hypertension, endothelial function, irbesartan, antihypertensive drugs, combination therapy

Introduction
Hypertension and cardiovascular risk

Several studies have shown that elevated blood pressure (BP) is a major risk factor for cardiovascular morbidity and mortality. This relationship is strong and continuous in a range of patient populations and age groups.1–5 Most of the major guidelines for the treatment of hypertension recommend that individuals with a BP ≥ 140/90 mmHg should be regarded as hypertensive, and treated in order to keep BP below this threshold. Systolic BP and diastolic BP (SBP and DBP, respectively) targets generally must be lower in patients at high cardiovascular risk and in those with diabetes or renal disease.6,7

Nearly 40 years ago, data from the Framingham Heart Study showed that SBP was more closely associated with the risk of cardiovascular disease than DBP. Although DBP was shown to be a more useful predictor of cardiovascular risk in hypertensive patients younger than 45 years, for the majority of hypertensive patients, the ability of SBP to predict ischemic cardiovascular disease was not improved by addition of
DBP data. The superior predictive ability of SBP was more recently confirmed by the Prospective Studies Collaboration, a meta-analysis of 61 prospective observational studies that recorded BP and cause-specific mortality. In this study, Lewington et al found that SBP at baseline was more informative than DBP as a predictor of stroke and mortality from ischemic heart disease. Moreover the study concluded that, in middle-aged individuals, prolonged reductions in usual SBP of only 2 mmHg would lead to substantial reductions in the incidence of death secondary to stroke (a 7% reduction) and other vascular causes (10%).

These data are supported by those of Stamler et al who found that SBP had a stronger association with cardiovascular risk than DBP in middle-aged and elderly individuals. At every level of DBP in this population, a higher SBP value was associated with greater cardiovascular risk and lower life expectancy.

Recently, Benetos et al aimed to determine whether the high cardiovascular mortality rate in treated hypertensive patients was due to hypertension or to the presence of associated risk factors and/or diseases. Using cardiovascular mortality data from treated hypertensive patients (n = 8893) and from untreated age- and gender-matched normotensive and hypertensive controls (n = 25,880) enrolled in the Investigations Préventives et Cliniques cohort, Benetos et al observed that the two-fold increase in cardiovascular and coronary mortality found in treated hypertensive patients persisted after adjustment for cardiovascular risk factors. Adjustment for SBP was necessary to make the mortality rates similar in the two populations. Subsequent inclusion of DBP in the model did not modify the between-group risk ratio. These results suggest that the increased cardiovascular mortality in treated hypertensive patients is mainly due to uncontrolled SBP levels.

Moreover, the incidence of most adverse cardiovascular events appears to follow a circadian pattern, reaching a peak in the morning shortly after waking and arising. The activity of many physiologic parameters fluctuates in a cyclical manner over 24 hours. It has been suggested that, during the post-awakening hours, the phases of hemodynamic, hematologic, and humoral cycles synchronize, thus creating an environment that predisposes to atherosclerotic plaque rupture and thrombosis in susceptible individuals. BP and heart rate follow a clear circadian rhythm. The increased SBP and DBP in the morning may act as a trigger for cardiovascular events, including myocardial infarction and stroke. The clinical implication of these observations is that antihypertensive therapy should provide BP control over the entire interval between doses.

There is strong evidence that sustain the high variability of BP over 24 hours. Furthermore, data from cross-sectional studies suggest that target organ damage is greater in hypertensive persons with high BP variability. The daytime SBP variability is a strong predictor of early carotid atherosclerosis progression and is useful to define the risk-benefit ratio of therapeutic approaches. A major impact of circadian BP patterns on the development of early carotid atherosclerosis has been demonstrated.

Endothelial physiology and dysfunction

Until a few years ago, the endothelium was considered to be just a cellular barrier between circulating blood and the arterial muscle wall, and was thought to be involved only in the processes of transport, metabolism, and coagulation. However, it has now been demonstrated that most of the pathophysiologic mechanisms that lead to atherosclerosis are located in the endothelium. The physiologic vascular action of the endothelium is modulated by a series of molecules controlling vasodilation and, to a minor extent, vasoconstriction. There is mounting evidence to suggest that hypertension is associated with endothelial abnormalities that are not likely to be related to high BP values, and more to hypertension per se.

Accordingly, endothelial dysfunction is not only improved by reduction of BP values, but may also be improved by pharmacologic treatment for hypertension. The mean feature of endothelium-mediated vasodilatation in hypertensive patients is the reduced availability of nitric oxide (NO). In patients with essential hypertension, activation of endothelial cells induces production of cyclo-oxygenase-dependent factors, such as free radicals, which are responsible for the impaired bioavailability of NO. When cyclo-oxygenase activity is blocked, the bioavailability of NO is immediately restored. In hypertensive patients, vitamin C infusion is able to improve acetylcholine (Ach)-induced vasodilatation.

NO bioavailability is usually decreased either by decreased formation or by enhanced removal. The presence of classic cardiovascular risk factors is associated with enhanced generation of radical oxygen species. Superoxide anions (O2−) play a pivotal role by reacting with NO, resulting in the formation of peroxynitrite (ONOO−), and hence decreasing bioavailability of NO. Studies with simultaneous measurement of relaxation and release of NO clearly show that endothelial cell signal transduction is altered in hypertension.

Moreover, in studies with healthy human subjects, several agonists (including Ach and bradykinin) have been
found to induce vasodilation when injected directly into the brachial or coronary circulation. 26–28 This vasodilation appears mainly regulated by specific NO synthase inhibitors, such as Nω-monomethyl-l-arginine (L-NMMA). In patients with essential hypertension, the response to endothelium-dependent agonists (mainly Ach or bradykinin) is blunted in different vascular regions when compared with healthy controls. This diminished relation response to Ach or bradykinin is, moreover, resistant to L-NMMA, which suggests the presence of compromised NO availability caused mainly by oxidative stress. 29–32

Some authors suggest that chronic inflammation may play a significant role in hypertension. A persistent low-grade inflammatory state could be associated with increased levels of cytokine plasma concentration. By impairing the capacity of the endothelium to generate vasodilating factors, particularly NO, elevated cytokines may lead to the development of endothelial dysfunction, chronically impaired vasodilation, and hypertension. 33

Other studies suggest that endothelial dysfunction may be reversible. Physical exercise, calcium channel blockers (CCBs), angiotensin-converting enzyme inhibitors (ACEIs), and angiotensin receptor antagonists (ARBs) are effective in improving flow-stimulated endothelium-dependent vasodilation in patients with hypertension and diabetes mellitus. 34,35

The ARB irbesartan shows high efficacy in lowering BP, to a degree comparable with ACEIs and superior to other ARBs, including losartan and valsartan. Moreover, irbesartan has been shown to be effective in both early- and late-stage diabetic nephropathy. 36 Irbesartan has furthermore demonstrated considerable cost savings over standard therapy, including beta-blockers, diuretics, and nondihydropyridine CCBs in all stages of kidney disease. Efficacy data from the Irbesartan Diabetic Nephropathy Trial and Reduction of Endpoints with the Angiotensin II Antagonist Losartan Study 37 has also demonstrated better cost savings with irbesartan than losartan in late-stage renal disease. While both irbesartan and losartan are registered for the treatment of late-stage diabetic nephropathy, irbesartan is also registered for early-stage diabetic nephropathy in the European Union. Some investigators claim there is a genuine value in using irbesartan instead of other ARBs in the treatment of hypertension. 38 and there is strong evidence of a positive impact from irbesartan in the treatment of hypertensive patients with endothelium-dependent vasodilation. 39 This effect is partially shared with other ARBs, although the specific activity of irbesartan has been shown in experimental studies. 40

Pharmacology
Irbesartan is nearly completely absorbed following oral administration, with an average absolute bioavailability of 60%–80%. About 25% of an administered radioactive dose is excreted in the urine and the remainder is eliminated in feces. 41 Several determinants of drug disposition, such as gastric acidity, gastric motility, glomerular filtration rate, plasma albumin, and renal and hepatic blood flow are altered in elderly subjects. 42 It is possible that one or more factors may contribute to the observed significant increases in the C_{max} and AUC of irbesartan. Results obtained in renally impaired patients indicated that renal impairment had no clinically important effects on the pharmacokinetics of irbesartan. 43 Food does not affect the bioavailability of irbesartan, so it can be administered without regard to meals. 44 Although there is an effect of age on the pharmacokinetics of irbesartan, based on the safety and efficacy profile, no adjustment in irbesartan dosage is necessary with respect to age or gender. 45

Irbesartan is a selective antagonist for the angiotensin II type 1 (AT1) receptor. The irbesartan concentration needed to reduce specific binding of 125I-angiotensin II to rat adrenal cortical microsomes by 50% is 0.9 nmol/L. Irbesartan has no active metabolites. 46

Efficacy studies of irbesartan
Effects on blood pressure
The effects of ARBs on hypertension are well known from the literature, and the efficacy of irbesartan in lowering BP is evident both in experimental and clinical studies. 47 All irbesartan regimens significantly reduced mean 24-hour ambulatory BP values and were well tolerated. Administration of irbesartan 150 mg once a day provides significant reduction of BP for 24 hours, equivalent to that obtained with the same total daily dose divided into two doses. 48

The antihypertensive effect of irbesartan on both SBP and DBP appears increased when administered in combination with diuretics. In a study by Mugellini et al, reduction of DBP and SBP with irbesartan-hydrochlorothiazide was comparable with that obtained with manidipine-delapril (−26.4/20.2 mmHg and −27.6/21.8 mmHg, respectively) and better than that of the respective monotherapies (−16.3/11.3 mmHg with delapril and −15.2/11.7 mmHg with irbesartan) in hypertensive patients with type 2 diabetes mellitus. 49

Recently, an uncontrolled, multicenter study has confirmed the efficacy of the combination of irbesartan and hydrochlorothiazide. 50 The aim of this large study was to compare the antihypertensive efficacy of valsartan 80 mg versus
Irbesartan 150 mg when combined with hydrochlorothiazide 12.5 mg. Untreated or uncontrolled hypertensive adults (n = 800) were enrolled by primary care physicians. After a five-week, open-label, lead-in phase in which all patients received 12.5 mg hydrochlorothiazide once daily, subjects whose BP remained uncontrolled (n = 464) were randomized to valsartan-hydrochlorothiazide (80/12.5 mg) or irbesartan-hydrochlorothiazide (150/12.5 mg). After eight weeks, the irbesartan-hydrochlorothiazide combination produced greater reductions in average SBP and DBP measured by home BP monitoring than did valsartan-hydrochlorothiazide (SBP −13.0 versus −10.6 mmHg, P = 0.0094; DBP −9.5 versus −7.4 mmHg, P = 0.0007, respectively). Comparable results were obtained between the groups for clinic BP measurements. The overall drug safety was similar between the two treatment groups.51

An irbesartan-hydrochlorothiazide fixed-dose combination has been approved for clinical use, and its efficacy and safety has recently been evaluated in a study of 96 hypertensive diabetic patients randomized to 12 months of double-blind treatment with doxazosin 4 mg/day or irbesartan 300 mg/day.52 At the end of the study, SBP and DBP were significantly (P < 0.01) reduced from 152 to 140 mmHg and from 97 to 87 mmHg, respectively, with doxazosin. SBP and DBP were reduced from 150 to 134 mmHg and from 94 to 83 mmHg, respectively, with irbesartan (P < 0.01). Irbesartan had significantly better antihypertensive efficacy than doxazosin (P < 0.05).53 In patients with increased DBP, irbesartan shows comparable efficacy to that of amlodipine. In a study of non-African-American patients with a seated DBP of 95–100 mmHg, irbesartan 150 mg/day did not show any significant difference in DBP-lowering effect compared with amlodipine 5 mg/day.54

In a recent study by Fogari et al, 94 hypertensive patients were randomized to valsartan 160 mg + amlodipine 5 mg or irbesartan 300 mg + hydrochlorothiazide 12.5 mg for 24 weeks after a four-week placebo period. Both combinations significantly reduced clinical seated and lying BP values, with no difference between treatments. BP changes from the lying to standing position were significantly greater in the irbesartan-hydrochlorothiazide group (−17.2/−9.1 mmHg) than in the valsartan-amlodipine group (−10.1/−1.9 mmHg, P < 0.05 for SBP and P < 0.01 for DBP versus irbesartan-hydrochlorothiazide). Both combinations were similarly effective in reducing ambulatory and clinical BP in very elderly hypertensive subjects.55

Compared with ACEIs, irbesartan has a similar effect on BP reduction, with fewer adverse events recorded for irbesartan. In a double-blind, randomized study, an irbesartan-based antihypertensive regimen reduced SBP/DBP by 40/30 mmHg after 12 weeks in patients with severe hypertension. This reduction was at least equivalent to that of a regimen using enalapril up to 40 mg. The irbesartan-based regimen had a better tolerability profile with fewer adverse events (55% versus 64%) and significantly less cough (2.5% versus 13.1%, P = 0.007).56 These results have been confirmed in a larger clinical trial comparing irbesartan and enalapril. Two hundred and thirty-eight patients were randomized to treatment, and the study was completed by 111 patients in the irbesartan group (dose titrated to 300 mg/day in 72.0% of patients) and 115 patients in the enalapril group (dose titrated to 20 mg/day in 76.5% of patients). BP reductions were similar in the two groups, both as measured in the clinic (DBP −12.7 ± 8.8 mmHg for irbesartan versus −12.4 ± 7.4 mmHg for enalapril; SBP −19.0 ± 14.1 mmHg versus −17.5 ± 14.0 mmHg, respectively) and by 24-hour ambulatory BP monitoring (DBP −9.4 ± 8.5 mmHg versus −8.8 ± 8.5 mmHg; SBP −14.7 ± 14.7 mmHg versus −12.6 ± 13.1 mmHg). The overall incidence of adverse events (40.0% for irbesartan, 51.2% for enalapril) was not statistically different between the treatment groups, although the incidence of adverse events, probably related to antihypertensive treatment, was significantly higher with enalapril than with irbesartan (24.6% versus 9.2%, respectively, P = 0.026), and were essentially accounted for by a higher incidence of cough (8.1% versus 0.9%, respectively).57

Compared with other ARBs, irbesartan shows equal or greater efficacy in reducing both SBP and DBP. In a study by Mancia et al, irbesartan was more effective than valsartan in reducing DBP and SBP at trough levels and in providing greater overall 24-hour BP lowering. In another study, after a three-week, single-blind, placebo lead-in period, 426 subjects were randomized to receive either irbesartan 150 mg or valsartan 80 mg for eight weeks. At the end of the study, irbesartan provided significantly greater reductions than valsartan for mean change from baseline in diastolic ambulatory BP at trough (−6.73 versus −4.84 mmHg, respectively, P = 0.035) and in mean systolic ambulatory BP at trough (−11.62 versus −7.5 mmHg, respectively, P < 0.01). Similar results were obtained for mean 24-hour diastolic ambulatory BP (−6.38 versus −4.82 mmHg, respectively, P = 0.023) and systolic ambulatory BP (−10.24 versus −7.76 mmHg, P < 0.01). Irbesartan also produced significantly greater reductions than valsartan for office-measured seated DBP (−10.46 versus −7.28 mmHg, respectively, P < 0.01) and SBP (−16.23 versus −9.96 mmHg, respectively, P < 0.01) and
Effects on vascular endothelium

Recent findings suggest that AT₁ receptor blockade improves superoxide production and NO bioavailability more than do other classes of antihypertensive agents. In a study by Brosnan et al, in vivo irbesartan, amlodipine, and hydrochlorothiazide-hydralazine produced similar reductions in BP values, but irbesartan caused a greater reduction in superoxide and p22phox in carotid arteries. Four-hour in vitro exposure to irbesartan decreased superoxide levels in the aorta and increased NO bioavailability in carotid arteries. Neither 30-minute incubation with irbesartan nor four hours with amlodipine or hydrochlorothiazide-hydralazine altered superoxide levels. Reduced expression of components of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase may contribute to these effects.

Moreover, a protective effect of AT₁ receptor blockers on endothelial function during postprandial hypertriglyceridemia has been reported in healthy subjects. In 2005, Ceriello et al demonstrated, for the first time, that irbesartan, like statins, is able to ameliorate the damage done to endothelial function by postprandial hyperglycemia and hypertriglyceridemia, oxidative stress, and inflammation in diabetic patients. These results appeared not to be linked to the BP-lowering effect and were obtained after short-term treatment. In this study, combination treatment of atorvastatin and irbesartan showed a more powerful effect on vascular damage compared with monotherapy using irbesartan or atorvastatin.

Pharmacodynamic data suggest that irbesartan at a dose of 300 mg provides more effective and persistent AT₁ blockade than losartan 100 mg. In a short-term (eight week) study by Kassler-Taub et al, after a placebo lead-in, 567 patients were randomized to once-daily therapy with placebo, losartan 100 mg, irbesartan 150 mg, or irbesartan 300 mg. At the end of the study, reductions from baseline in seated DBP and seated SBP with irbesartan 300 mg were greater than those obtained with losartan 100 mg by −3.0 and −5.1 mmHg, respectively (P < 0.01 for both comparisons). Larger reductions were also demonstrated at weeks 1 and 4 (P < 0.01 and P = 0.017, respectively, for DBP and SBP) of the study, and the antihypertensive effects of the treatments were not significantly different.

The renoprotective effect of irbesartan has been tested in a study by Rossing et al. In this study, 52 hypertensive patients with type 2 diabetes and microalbuminuria already on antihypertensive treatment were included. After a two-month wash-out of other drugs, patients were randomized to receive irbesartan 300, 600, and 900 mg once daily. After a 10-week treatment period, ultrahigh doses of irbesartan were well tolerated and provided additional renoprotection independent of changes in BP values and glomerular filtration rate, compared with irbesartan 300 mg.

Administration of irbesartan twice daily has been evaluated in a study by Polonía et al who investigated whether blockage of angiotensin II receptors by irbesartan could reverse the nondipper circadian rhythm of BP to a dipper pattern in 12 black salt-sensitive hypertensive patients on a high sodium diet (300 mmol per day) after a two-week placebo administration, followed by two weeks on irbesartan 150 mg/day, two weeks on placebo, and two weeks on irbesartan 300 mg/day. On the last day of placebo, and of the irbesartan 150 mg/day and irbesartan 300 mg/day treatments, 24-hour BP and urinary 24-hour excretion of sodium and potassium were measured. Compared with placebo, irbesartan significantly increased serum potassium and plasma renin activity and reduced fractional excretion of potassium and plasma aldosterone levels in a dose-dependent manner, without significant changes in body weight. The authors concluded that irbesartan can reverse the nondipper BP profile in salt-sensitive hypertensive patients on a high-salt diet, restoring the nocturnal BP decline by a predominantly dose-dependent reduction of night time BP. This result occurred independently of increased natriuresis. Evidence has been accumulating to suggest that ambulatory BP values are more strongly correlated with markers of cardiovascular disease than are clinic BP values.

The main studies that showed a significant effect of irbesartan in reducing microalbuminuria and decreasing the risk of diabetic nephropathy were Irbesartan Microalbuminuria type 2 Diabetes in Hypertensive Patients (IRMA II) and Irbesartan in Diabetic Nephropathy Trial (IDNT). These are two long-term (2–3 year) trials showing that the irbesartan is effective in reducing the progression of renal disease in patients with type 2 diabetes and high BP. In each trial, the standard of care for diabetes mellitus was maintained. Using conventional antihypertensive therapy, including diuretics, beta-blockers, and CCBs (but not ACEIs or other ARBs), BP control was similar in the placebo- and ARB-treated groups.

The IRMA II study (Table 1) evaluated the renoprotective effect of irbesartan, in hypertensive patients with type 2 diabetes and microalbuminuria. This multinational, randomized, double-blind, placebo-controlled study enrolled a total
of 590 hypertensive patients with type 2 diabetes and persistent microalbuminuria who received irbesartan at a dose of either 150 mg daily or 300 mg daily, or placebo. The primary efficacy measure was the time from the baseline visit to the first detection of overt nephropathy, defined by a urinary albumin excretion rate in an overnight specimen >200 μg/min and at least 30% higher than the baseline rate on at least two consecutive visits. At the end of the study, nephropathy developed in 30 patients in the placebo group, compared with 19 patients in the 150 mg irbesartan group and 10 patients in the 300 mg irbesartan group. The unadjusted hazard ratio (HR) for diabetic nephropathy was 0.61 (P = 0.08) in the 150 mg group and 0.30 (P < 0.001) in the 300 mg group. The average BP during the course of the entire study was 144/83 mmHg in the placebo group, 143/83 mmHg in the 150 mg irbesartan group, and 141/83 mmHg in the 300 mg irbesartan group (P = 0.004 for the comparison of SBP between the placebo group and the combined irbesartan groups).

After adjustment for BP achieved during the study and the baseline level of microalbuminuria, the HR for diabetic nephropathy was 0.56 in the 150 mg group (P = 0.05) and 0.32 in the 300 mg group (P < 0.001). Serious adverse events were less frequent among the patients treated with irbesartan (P = 0.02). Irbesartan reduced the level of urinary albumin excretion throughout the study. In the irbesartan 150 mg group, urinary albumin excretion decreased by 24% and, in the 300 mg group, decreased by 38%, whereas the placebo group had a 2% decrease (P < 0.001 for the comparison between placebo and combined irbesartan groups). There was a significantly smaller reduction in the level of albuminuria in the 150 mg group than in the 300 mg group (P < 0.001).

During this 24-month study, overt nephropathy developed in 30 patients in the placebo group, compared with 19 patients in the 150 mg group (P = 0.08) and 10 patients in the 300 mg group (P < 0.001). The unadjusted HR for diabetic nephropathy was 0.61 (P = 0.08) in the 150 mg group and 0.30 (P < 0.001) in the 300 mg group. After adjustment for the baseline level of microalbuminuria and the BP achieved during the study, the HR for diabetic nephropathy was 0.56 in the 150 mg group and 0.32 in the 300 mg group (P < 0.001). At the three-month visit, the decrease in creatinine clearance for the placebo group and the 300 mg irbesartan group separated and continued to diverge. The decline in creatinine clearance during the initial three-month period was greater than the sustained decline from three months to 24 months. The initial declines were 0.9, 1.0, and 1.9 in the placebo, and irbesartan 150 mg and 300 mg groups, respectively, compared with declines of 0.1, 0.2, and 0.2 between months 3 and 24. Neither the initial decline nor the sustained decline differed significantly among the three groups. Irbesartan reduced the level of urinary albumin excretion throughout the study. Urinary albumin decreased by 24% in the 150 mg group, 38% in the 300 mg group, and 2% in the placebo group.
group ($P < 0.001$ for the comparison between placebo and the combined irbesartan groups). There was a significantly smaller reduction in the level of albuminuria in the 150 mg group than in the 300 mg group ($P < 0.001$).

In the other relevant large study, the IDNT study compared the renoprotective effect of irbesartan and amlodipine in patients with type 2 diabetes and microalbuminuria (Table 2), beyond the effect of these two drugs on BP reduction. It was a prospective, randomized, double-blind, placebo-controlled study including 1175 patients from 210 clinical centers. Patients enrolled in this study had hypertension and nephropathy due to type 2 diabetes. Patients were randomized to receive irbesartan 300 mg/day, amlodipine 10 mg/day, or placebo. Groups were compared according to time to the primary composite endpoint of a doubling of baseline serum creatinine concentration, development of end-stage renal disease, and death from any cause. The mean follow-up duration was 2.6 years. At the end of the study, treatment with irbesartan was associated with a 20% and 23% reduction in risk of the primary composite endpoint compared with placebo and amlodipine, respectively ($P = 0.006$). The relative risk of doubling of the serum creatinine concentration was 33% and 37% lower in the irbesartan group compared with the placebo and amlodipine groups ($P = 0.003$ and $P < 0.001$, respectively). Treatment with irbesartan was associated with a significantly lower risk of end-stage renal disease ($-23\%$) compared with that observed in the other groups ($P = 0.07$ for both comparisons). These results were not affected by reduction in BP values. The increase in serum creatinine levels was slower in the irbesartan group compared with the placebo ($-24\%$) and amlodipine ($21\%$) groups ($P = 0.008$ and $P = 0.002$, respectively). No significant differences between groups were observed in the rate of death from any cause or in the cardiovascular composite endpoint.

Although the IRMA II and IDNT studies provided strong support for the beneficial effect of irbesartan in renoprotection, both studies included patients with hypertension who had been previously treated with antihypertensive drugs. In a short-term study, irbesartan was administered to newly diagnosed drug-naive patients; the effects of irbesartan 150 mg bid on microalbuminuria were observed in normotensive type 2 diabetic patients, suggesting that the renoprotective action of irbesartan is probably due to a direct action on renal hemodynamics and glomerular morphology.57

More recently, studies have demonstrated a precise role for irbesartan and statins in regulation of vascular dysfunction. In the Endothelial Protection, AT1 Blockade and Cholesterol-Dependent Oxidative Stress (EPAS) trial, the investigators showed that statin and AT1 blocker therapy independently and in combination improved both the antiatherosclerotic endothelial expression quotient and endothelial function. In this study, 60 patients with stable coronary artery disease undergoing elective coronary artery bypass grafting surgery were randomized four weeks before surgery to no ARBs and/or statins (controls), pravastatin 40 mg/day, irbesartan 150 mg/day, or pravastatin in combination with irbesartan at the same dosages. The primary endpoint was a priori therapy-dependent regulation of the antiatherosclerotic endothelial expression calculated marker of endothelial regulation. At the end of the study, association of irbesartan and pravastatin significantly improved endothelial expression of antiatherosclerotic and proatherothrombotic genes and endothelial function in arteries in these patients with coro-

### Table 2 The IDNT study

<table>
<thead>
<tr>
<th>Title</th>
<th>IDNT (Irbesartan Diabetic Nephropathy Trial)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study</td>
<td>Prospective randomized, multicenter, double-blind placebo-controlled study</td>
</tr>
<tr>
<td>Design</td>
<td>Groups were compared with regard to the time to the primary composite endpoint</td>
</tr>
<tr>
<td>Target BP</td>
<td>135/85 mmHg or less in all groups</td>
</tr>
<tr>
<td>Patients (n)</td>
<td>1,715</td>
</tr>
<tr>
<td>Patient characteristics</td>
<td>Type 2 diabetes</td>
</tr>
<tr>
<td>Primary endpoint</td>
<td>Comparison between irbesartan and amlodipine efficacy in protection against the progression of nephropathy due to type 2 diabetes, independently of BP reduction</td>
</tr>
<tr>
<td>Secondary endpoints</td>
<td>Overall mortality in the two treatment groups</td>
</tr>
<tr>
<td>Rates of cardiovascular events in the two treatment groups</td>
<td></td>
</tr>
<tr>
<td>Treatments</td>
<td>Irbesartan 300 mg/day</td>
</tr>
<tr>
<td>Amlodipine 10 mg/day</td>
<td></td>
</tr>
<tr>
<td>Results (primary endpoint)</td>
<td>Irbesartan reduction of composite primary endpoint 20% lower versus placebo and 23% versus amlodipine$^{1,3}$</td>
</tr>
<tr>
<td>Relative risk of doubling of serum creatinine concentration 33% lower with irbesartan versus placebo and 37% versus amlodipine$^{3,4}$</td>
<td></td>
</tr>
<tr>
<td>Relative risk of end-stage renal disease was 23% lower in irbesartan group than in both other groups$^a$</td>
<td></td>
</tr>
<tr>
<td>Results (secondary endpoints)</td>
<td>No significant differences in the rate of death from any cause and in the cardiovascular composite endpoint</td>
</tr>
<tr>
<td>Conclusions</td>
<td>Significant reduction of progression from microalbuminuria to nephropathy in diabetic patients treated with irbesartan Renoprotection independent of blood pressure reduction</td>
</tr>
</tbody>
</table>

$^a$ $P = 0.02$ for irbesartan versus placebo; $P = 0.006$ for irbesartan vs amlodipine; $P = 0.003$ for irbesartan versus placebo; $P < 0.001$ for irbesartan versus amlodipine; $P = 0.07$ for both comparisons.
nary artery disease. Moreover, preoperative therapy with irbesartan and pravastatin and their combination improved endothelial function in internal mammary artery rings.68

Recently, many studies have focussed on molecular markers of the inflammatory mechanisms involved in atherogenesis, and particular attention has been given to inflammatory molecules which interact with the endothelium, such as tumor necrosis factor-α, vascular cell adhesion molecule, and superoxides. In a study by Navalkar et al, irbesartan significantly improved levels of inflammatory molecules in 33 normotensive patients with coronary artery disease, and the maximal suppression of inflammatory markers was observed after 12 weeks.69 In another study, treatment with irbesartan was effective in reducing the pro-oxidative environment seen in patients with coronary artery disease. Lag time for LDL oxidation increased 32% at 12 weeks, suggesting that increased resistance of LDL modification during serum and lipid peroxidation decreased by 36% with irbesartan compared with placebo. In addition, superoxide levels and monocyte-binding capacity were also significantly reduced in coronary artery disease patients receiving irbesartan.70

**Conclusions**

Ibesartan is an angiotensin II receptor type 1 antagonist which has demonstrated efficacy in reducing BP in patients with high cardiovascular risk. In comparative trials, irbesartan seems significantly more effective than other ARBs in the treatment of mild to moderate essential hypertension, and is as effective as enalapril or atenolol. Many studies also show an additive antihypertensive effect when hydrochlorothiazide is added to irbesartan monotherapy. In hypertensive patients, the presence of an abnormal circadian BP rhythm as a result of lack of nocturnal BP decrease (nondippers) has been reported to be associated with a higher risk of cardiovascular end organ damage and a poorer prognosis for cardiovascular events compared with dippers (who show a normal nocturnal BP decrease). Ibesartan is able to modulate circadian BP rhythms and thereby significantly modifies the risk of organ damage due to hypertension and endothelial dysfunction, such as increased intima media thickness and left ventricular hypertrophy. Ibesartan also induces statistically significant regression of left ventricular mass in patients with hypertension and left ventricular hypertrophy, and preliminary evidence suggests it has beneficial hemodynamic effects in patients with heart failure.

Moreover, irbesartan counteracts a number of other defects that lead to high cardiovascular risk, in particular insulin resistance and endothelial dysfunction. The so-called ancillary effects of irbesartan, which are partially shared by other ARBs, have been highlighted in recent studies. Particular interest has arisen about the effects of irbesartan on vascular dysfunction, which represents one of the major mechanisms that lead to atherosclerosis, and metabolic and cardiovascular diseases. A beneficial effect of irbesartan on glomerular filtration and microalbuminuria has been established in large clinical trials, such as IDNT and IRMA II. Many data suggest a relationship between BP and endothelial dysfunction, so the role of irbesartan in modulation of vasodilatation and cytokines disorders could be explained in further experimental and clinical studies. Furthermore, the connection between insulin resistance, hypertension, and endothelial dysfunction, as well as the effects of ARBs on these mechanisms, has not been yet completely explained. In conclusion irbesartan is useful for clinicians for treatment of hypertension and prevention of organ damage, and appears well tolerated also at high dosage.

**Disclosures**

The authors report no conflict of interest in this work.

**References**


